Skip to content

Clinical trials

Phase 1/2 Small Cell Lung Carcinoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Small Cell Lung Carcinoma Phase: Phase 1/2 Clear all

157 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20031
20041
20062
20075
20084
20092
20103
20112
20124
20136
20147
20155
20166
201713
20185
20198
202014
202112
20225
202310
20246
202512
202619

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed49
Recruiting41
Terminated30
Unknown status14
Active, not recruiting11
Not yet recruiting6
Withdrawn6

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)11
Eli Lilly and Company3
Incyte Biosciences International Sàrl3
Suzhou Zelgen Biopharmaceuticals Co.,Ltd3
Washington University School of Medicine3
AbbVie2
Amgen2
Anhui Provincial Hospital2
Astellas Pharma Global Development, Inc.2
Bayer2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Small Cell Lung Carcinoma157
Carcinoma, Non-Small-Cell Lung43
Lung Neoplasms20
Ovarian Neoplasms18
Breast Neoplasms17
Triple Negative Breast Neoplasms17
Squamous Cell Carcinoma of Head and Neck16
Stomach Neoplasms16
Melanoma15
Colorectal Neoplasms14

Trials

Showing 76 to 100 of 157. Each trial links to its page on Pharma Observatory.

57 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.